

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
Please do not report the images to the
Image Problem Mailbox.




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/58, A61K 31/34, C07D 405/06, C07C 317/24, 317/14		A1	(11) International Publication Number: WO 98/43966 (43) International Publication Date: 8 October 1998 (08.10.98)
(21) International Application Number: PCT/CA98/00302			(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 31 March 1998 (31.03.98)			
(30) Priority Data: 60/042,535 2 April 1997 (02.04.97) US 9709356.1 7 May 1997 (07.05.97) GB			
(71) Applicant (for all designated States except US): MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA).			Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(72) Inventors; and (75) Inventors/Applicants (for US only): LEGER, Serge [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GRIMM, Erich [DE/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). PRASIT, Petpiboon [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA).			
(74) Agent: MURPHY, Kevin, P.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College, Montreal, Quebec H3A 2Y3 (CA).			

(54) Title: ALPHA-METHYLENE GAMMA LACTONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS

(57) Abstract

The invention encompasses the novel compound of Formula (I) as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula (I).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Republic of Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION

ALPHA-METHYLENE GAMMA LACTONES AS SELECTIVE
CYCLOOXYGENASE-2 INHIBITORS

5 BACKGROUND OF THE INVENTION

This invention relates to methods of treating cyclooxygenase mediated diseases and certain pharmaceutical compositions therefor.

Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit

10 hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Initially, only one form of cyclooxygenase was known, this corresponding to cyclooxygenase-1 (COX-1) or the constitutive enzyme, as originally identified in bovine seminal vesicles.

15 More recently the gene for a second inducible form of cyclooxygenase, cyclooxygenase-2 (COX-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources. This enzyme is distinct from the COX-1 which has been cloned, sequenced and characterized from various sources including the sheep, the mouse and

20 man. The second form of cyclooxygenase, COX-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, COX-1, is responsible, in large part, for endogenous

25 basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, COX-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in

30 response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of COX-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential

35 anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced

potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.


Furthermore, such a compound will also inhibit 5 prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labour, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, for decreasing bone loss particularly in postmenopausal women 10 (i.e. treatment of osteoporosis) and for the treatment of glaucoma.

The potential utilities of selective cyclooxygenase-2 inhibitors are discussed in the following articles:

1. John Vane, "Towards a better aspirin" in Nature, Vol. 367, pp. 215-216, 1994
- 15 2. Bruno Battistini, Regina Botting and Y.S. Bakhle, " COX-1 and COX-2: Toward the Development of More Selective NSAIDs" in Drug News and Perspectives, Vol. 7, pp. 501-512, 1994.
3. David B. Reitz and Karen Seibert, "Selective Cyclooxygenase Inhibitors" in Annual Reports in Medicinal Chemistry, James A. 20 Bristol, Editor, Vol. 30, pp. 179-188, 1995.

SUMMARY OF THE INVENTION


The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising 25 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.



The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

5 DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.



10

I

X is (a) O,
 (b) CH₂,
 (c) CH(C₁₋₃alkyl),
 (d) C(C₁₋₃alkyl)₂ or
 (e) a bond;

15

Y is (a) O,
 (b) H,OH or
 (c) H,H;

20

Ar is (a) phenyl or
 (b) pyridyl;

25 each of R¹, R², R³, or R⁴ is independently
 (a) hydrogen or,
 (b) C₁₋₆alkyl;

each of R⁵ or R⁶ is independently
 30 (a) hydrogen,

- (b) halo,
- (c) C₁₋₄alkyl,
- (d) C₁₋₄alkoxy, or
- (e) C₁₋₄alkylthio;

5

R⁷ is (a) NH₂ or
 (b) CH₃.

A preferred embodiment of the invention is that
 10 wherein X is O.

Another preferred embodiment of the invention is that
 wherein Y is O.

Another preferred embodiment of the invention is that
 wherein X and Y are both O.

15 Another preferred embodiment of the invention is that
 wherein R¹ and R² are both CH₃.

Another preferred embodiment of the invention is that
 wherein R⁵ is hydrogen or F.

20 Another preferred embodiment of the invention is that
 wherein R⁷ is CH₃.

Exemplifying this invention are:

3-[(E)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethyli-
 dene]tetrahydro-2-furanone,

25 5,5-Dimethyl-3-[(E)-1-(4-(methylsulfonyl)phenyl)-1-
 phenylmethyliidene]tetrahydro-2-furanone,

3-[(E)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-
 methylidene]tetrahydro-2-furanone,

3-[(Z)-1-(3-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-
 methylidene]tetrahydro-2-furanone,

30 5-Methyl-3-[(E)-1-(4-(methylsulfonyl)phenyl)-1-phenyl-
 methylidene]tetrahydro-2-furanone,

3-[(E)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-
 methylidene]-5,5-dimethyltetrahydro-2-furanone,

35 3-[(Z)-1-(3-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-
 methylidene]-5,5-dimethyltetrahydro-2-furanone,

5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(2-
 pyridyl)methylidene] tetrahydro-2-furanone,

3-[(Z)-1-(4-Chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-methylidene]-5,5-dimethyltetrahydro-2-furanone,
 4,4-Dimethyl-3-[1-(4-(methylsulfonyl)phenyl)-1-phenyl-methylidene]tetrahydro-2-furanone,
 5 4-[Cyclopentyliden(phenyl)methyl]phenyl methyl sulfone,
 2[(E)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethylidene]-1-cyclopentanone, 5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(3-pyridyl)methylidene] tetrahydro-2-furanone,
 5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(4-pyridylmethylidene) tetrahydro-2-furanone, and
 10 4-[Cyclobutyliden(phenyl)methyl]phenyl methyl sulfone.

The following abbreviations have the indicated meanings:

15	AA	=	arachidonic acid
	Ac	=	acetyl
	AIBN	=	2,2'-azobisisobutyronitrile
	Bn	=	benzyl
	CSA	=	camphor sulfonic acid
20	DMAP	=	4-(dimethylamino)pyridine
	DMF	=	N,N-dimethylformamide
	DMSO	=	dimethyl sulfoxide
	Et ₃ N	=	triethylamine
	HBSS	=	Hanks balanced salt solution
25	HEPES	=	N-[2-Hydroxyethyl]piperazine-N1-[2-ethanesulfonic acid]
	HWB	=	human whole blood
	KHMDS	=	potassium hexamethyldisilazane
	LDA	=	lithium diisopropylamide
30	LPS	=	lipopolysaccharide
	MMPP	=	magnesium monoperoxyphthalate
	Ms	=	methanesulfonyl = mesyl
	MsO	=	methanesulfonate = mesylate
	NSAID	=	non-steroidal anti-inflammatory drug
35	OXONE™	=	2KHSO ₅ - KHSO ₄ - K ₂ SO ₄
	PCC	=	pyridinium chlor chromate
	PDC	=	pyridinium dichromate

	Ph	=	phenyl
	r.t.	=	room temperature
	rac.	=	racemic
	Tf	=	trifluoromethanesulfonyl = triflyl
5	TfO	=	trifluoromethanesulfonate = triflate
	TFOH	=	trifluoromethane sulfonic acid
	THF	=	tetrahydrofuran
	TLC	=	thin layer chromatography
	Ts	=	p-toluenesulfonyl = tosyl
10	TsO	=	p-toluenesulfonate = tosylate
	SO ₂ Me	=	methyl sulfone
	SO ₂ NH ₂	=	sulfonamide

Alkyl group abbreviations

15	Me	=	methyl
	Et	=	ethyl
	n-Pr	=	normal propyl
	i-Pr	=	isopropyl
	n-Bu	=	normal butyl
20	i-Bu	=	isobutyl
	s-Bu	=	secondary butyl
	t-Bu	=	tertiary butyl
	c-Pr	=	cyclopropyl
	c-Bu	=	cyclobutyl
25	c-Pen	=	cyclopentyl
	c-Hex	=	cyclohexyl

Dose Abbreviations

	bid	=	bis in die = twice daily
30	qid	=	quater in die = four times a day
	tid	=	ter in die = three times a day

The term "alkyl" means linear, branched or cyclic structures and combinations thereof, containing the indicated number of carbon atoms. Examples of alkyl groups include methyl, ethyl, cyclopropyl, isopropyl, butyl, t-butyl, pentyl, hexyl, cyclohexyl, heptyl, pentadecyl, eicosyl, 3,7-diethyl-2,2-dimethyl- 4-propynonyl, and the like.

"Alkoxy" means alkoxy groups of the indicated number of carbon atoms of a straight, branched, or cyclic configuration. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropoxy, cyclohexyloxy, and the like.

5 "Alkylthio" means alkylthio groups of the indicated number of carbon atoms of a straight, branched or cyclic configuration.

Examples of alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH₂CH₂CH₃.

10 Halogen includes F, Cl, Br, and I.

In another embodiment, the invention encompasses pharmaceutical compositions for inhibiting COX-2 and for treating COX-2 mediated diseases disclosed herein comprising a pharmaceutically acceptable carrier and non-toxic therapeutically effective amount of a compound of formula I as described above.

15 In yet another embodiment, the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising:

20 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.

Optical Isomers - Diastereomers - Geometric Isomers

25

Some of the compounds described herein contain one or more asymmetric centres and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved,

30 enantiomerically pure forms and pharmaceutically acceptable salts thereof.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

35

Salts

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.

5 When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, adipic, aspartic, 1,5-naphthalenedisulfonic, benzenesulfonic, benzoic, 10 camphorsulfonic, citric, 1,2-ethanedisulfonic, ethanesulfonic, ethylenediaminetetraacetic, fumaric, glucoheptonic, gluconic, glutamic, hydriodic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, 2-naphthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, 15 pivalic, propionic, salicylic, stearic, succinic, sulfuric, tartaric, p-toluenesulfonic acid, undecanoic, 10-undecenoic, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, methanesulfonic, phosphoric, sulfuric and tartaric acids.

20 It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

Utilities

25 The Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, 30 including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumour growth and hence can be used in the treatment of cancer.

35 Compound 1 may also be of use in the treatment and/or prevention of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumour angiogenesis.

Compound I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labour, asthma and eosinophil related disorders. It will also be of use in 5 the treatment of Alzheimer's disease, for decreasing bone loss particularly in postmenopausal women (i.e. treatment of osteoporosis) and for treatment of glaucoma.

By virtue of its high inhibitory activity against COX-2 and/or its specificity for COX-2 over COX-1, compound I will prove useful as an 10 alternative to conventional NSAID'S, particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anaemia such as 15 hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; those prior to surgery or taking anticoagulants.

Pharmaceutical Compositions

20 For the treatment of any of these cyclooxygenase mediated diseases compound I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes 25 subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.

30 As indicated above, pharmaceutical compositions for treating COX-2 mediated diseases as defined may optionally include one or more ingredients as listed above.

The pharmaceutical compositions containing the active 35 ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical

compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain 5 the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn 10 starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the 15 gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard 20 gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, 25 or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy- 30 propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide 35 with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as

polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example 5 ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, 10 sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an 15 anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting 20 agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a 25 vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation 30 products of the said partial esters with ethylene oxide, for example polyoxy-ethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening 35 agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a steril injectable aqueous or oleagenous

suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a 5 non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are 10 conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compound I may also be administered in the form of a 15 suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

20 For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration 25 enhancer, preservative system, and emollient.

Dose Ranges

Dosage levels of the order of from about 0.01 mg to about 140 30 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per 35 patient per day.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary

depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

10 It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

15

Combinations with Other Drugs

Similarly, compound I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating COX-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin; a 20 potentiator including caffeine; an H₂-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo- 25 desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a prostaglandin including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating cyclooxygenase mediated 30 diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of 35

Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

Methods of Synthesis

The compounds of the present invention can be prepared according to the following methods.

5


Method 1

A Friedel-Crafts reaction between a benzoyl chloride 1 and thioanisole 2 yields benzophenone 3. Lactone 4 is condensed with 3 using 10 a suitable base such as LDA to give alcohol 5. Alcohol 5 is dehydrated to 6 using an acid, such as TfOH or CSA or by conversion to the mesylate; 6 is obtained as a mixture of the E and Z isomers. Sulfide 6 is oxidized to the sulfone mixture 7 using MMPP or OXONE™, followed by chromatographic separation to obtain compound Ia.

15


Alternatively, the mixture of isomers 6 can be separated and the desired precursor to Ia oxidized. The undesired isomer of 6, and compound 8, can be isomerized to the desired isomers by treatment with a protonic acid or by photochemical means.

To prepare the compounds I in which Ar is pyridyl, the 20 ketone 12 (Method 2) is used in place of benzophenone 4. In this case, the oxidation step (6 - 7) is done with OXONE™ in order to avoid formation of a pyridine-N-oxide.




Method 2

Bromothioanisole 9 is transmetallated with an alkyl lithium, followed by reaction with aldehyde 10, to produce alcohol 11. 5 Oxidation with a mild reagent such as MnO_2 in ethyl acetate gives ketone 12, which is then used in place of benzophenone 3 in Method 1.

Method 3

A Friedel-Crafts reaction between acid chloride 13 and thioanisole 2 yields the ketone 14, which upon reaction with an aryl lithium 15 yields tertiary alcohol 16. Dehydration of the latter with a proton acid produces a mixture of the stereoisomers 17, which is 15 oxidized to the mixture of sulfones 18 by MMPP or other suitable oxidant. Allylic oxidation with a reagent such as chromium trioxide yields 19 as a mixture of isomers. Chromatographic separation then yields the stereoisomers 20 and Ib.


20



Method 4

Preparation of the sulfonamides ($R^7 = NH_2$) is carried out according to Method 4. The intermediate 6 can be selectively oxidized to sulfoxide 21 by using one equivalent of an oxidizing agent such as MMPP. The free thiol 22 is obtained by reacting 21 with trifluoroacetic anhydride, followed by treatment with triethylamine in methanol. Oxidation of thiol 22 with Cl_2 in acetic acid yields a sulfonyl chloride intermediate, which reacts with ammonia to yield the isomeric mixture of sulfonamide 23. The isomers are separated by chromatography to yield 24 and the desired Ic.

10



Method 5

An alternative preparation of Ia is outlined in Method 5.

Condensation of lactone 4 with ester 25 is brought about by reaction with 5 an anhydrous base such as LDA to yield ketolactone 26. The enol triflate 27 is obtained as a mixture of stereoisomers by reacting 25 with triflic anhydride. A Suzuki coupling of 27 and 28 yields the mixture of stereoisomers 6, which is carried through to compound Ia as in Method 1.

10





Representative Compounds

Table I illustrates compounds of formula I, which are representative of the present invention.


Example 1




Example 6




Example 2




Example 7




Example 3




Example 8




Example 4




Example 9














Example 5



Example 10







Assays for Determining Biological Activity

5 The compound of Formula I can be tested using the following assays to determine their COX-2 inhibiting activity.

INHIBITION OF CYCLOOXYGENASE ACTIVITY

10 Whole cell assays for COX-2 and COX-1 using CHO transfected cell lines
 Chinese hamster ovary (CHO) cell lines which have been stably transfected with an eukaryotic expression vector pCDNAIII containing either the human COX-1 or COX-2 cDNA's are used for the assay. These cell lines are referred to as CHO [hCOX-1] and CHO

15 [hCOX-2], respectively. For cyclooxygenase assays, CHO[hCOX-1] cells from suspension cultures and CHO[hCOX-2] cells prepared by trypsinization of adherent cultures are harvested by centrifugation (300 x g, 10 min) and washed once in HBSS containing 15 mM HEPES, pH 7.4, and resuspended in HBSS, 15 mM HEPES, pH 7.4, at a cell concentration of 1.5×10^6 cells/ml. Drugs to be tested are dissolved in DMSO to 66.7-fold the highest test drug concentration. Compounds are typically tested at 8 concentrations in duplicate using serial 3-fold serial dilutions in DMSO of the highest drug concentration. Cells (0.3×10^6 cells in 200 μ l) are preincubated with 3 μ l of the test drug or DMSO vehicle for 15 min at

20 37C. Working solutions of peroxide-free AA (5.5 μ M and 110 μ M AA for the CHO [hCOX-1] and CHO [COX-2] assays, respectively) are prepared by a 10-fold dilution of a concentrated AA solution in ethanol into HBSS

25

containing 15 mM HEPES, pH 7.4. Cells are then challenged in the presence or absence of drug with the AA/HBSS solution to yield a final concentration of 0.5 μ M AA in the CHO[hCOX-1] assay and a final concentration of 10 μ M AA in the CHO[hCOX-2] assay. The reaction is 5 terminated by the addition of 10 μ l 1 N HCl followed by neutralization with 20 μ l of 0.5 N NaOH. The samples are centrifuged at 300 x g at 4C for 10 min, and an aliquot of the clarified supernatant is appropriately diluted for the determination of PGE₂ levels using an enzyme-linked immunoassay for PGE₂ (Correlate PGE₂ enzyme immunoassay kit, 10 Assay Designs, Inc.). Cyclooxygenase activity in the absence of test compounds is determined as the difference in PGE₂ levels of cells challenged with arachidonic acid versus the PGE₂ levels in cells mock-challenged with ethanol vehicle. Inhibition of PGE₂ synthesis by test compounds is calculated as a percentage of the activity in the presence of 15 drug versus the activity in the positive control samples.

Assay of COX-1 Activity from U937 cell microsomes

U 937 cells are pelleted by centrifugation at 500 x g for 5 min 20 and washed once with phosphate-buffered saline and repelleted. Cells are resuspended in homogenization buffer consisting of 0.1 M Tris-HCl, pH 7.4, 10 mM EDTA, 2 μ g/ml leupeptin, 2 μ g/ml soybean trypsin inhibitor, 2 μ g/ml aprotinin and 1 mM phenyl methyl sulfonyl fluoride. The cell suspension is sonicated 4 times for 10 sec and is centrifuged at 25 10,000 x g for 10 min at 4° C. The supernatant is centrifuged at 100,000 x g for 1 hr at 4° C. The 100,000 x g microsomal pellet is resuspended in 0.1 M Tris-HCl, pH 7.4, 10 mM EDTA to approximately 7 mg protein/ml and stored at -80° C.

Microsomal preparations are thawed immediately prior to 30 use, subjected to a brief sonication, and then diluted to a protein concentration of 125 μ g/ml in 0.1 M Tris-HCl buffer, pH 7.4 containing 10 mM EDTA, 0.5 mM phenol, 1 mM reduced glutathione and 1 μ M hematin. Assays are performed in duplicate in a final volume of 250 μ l. Initially, 5 μ l of DMSO vehicle or drug in DMSO are added to 20 μ l of 0.1 35 M Tris-HCl buffer, pH 7.4 containing 10 mM EDTA in wells of a 96-well polypropylene titre plate. 200 μ l of the microsomal preparation are then added and pre-incubated for 15 min at room temperature before

addition of 25 μ l of 1 M arachidonic acid in 0.1 M Tris-HCl and 10 mM EDTA, pH 7.4. Samples are incubated for 40 min at room temperature and the reaction is stopped by the addition of 25 μ l of 1 N HCl. Samples are neutralized with 25 μ l of 1 N NaOH prior to quantitation of PGE2

5 content by radioimmunoassay (Dupont-NEN or Amersham assay kits). Cyclooxygenase activity is defined as the difference between PGE2 levels in samples incubated in the presence of arachidonic acid and ethanol vehicle.

10 Assay of the activity of purified human COX-2

The enzyme activity is measured using a chromogenic assay based on the oxidation of N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) during the reduction of PGG2 to PGH2 by

15 COX-2 (Copeland et al. (1994) Proc. Natl. Acad. Sci. 91, 11202-11206).

Recombinant human COX-2 is purified from Sf9 cells as previously described (Percival et al (1994) Arch. Biochem. Biophys. 15, 111-118). The assay mixture (180 μ L) contains 100 mM sodium phosphate, pH 6.5, 2 mM genapol X-100, 1 μ M hematin, 1 mg/ml gelatin

20 , 80-100 units of purified enzyme (One unit of enzyme is defined as the amount of enzyme required to produce an O.D. change of 0.001/min at 610 nm) and 4 μ L of the test compound in DMSO. The mixture is pre-incubated at room temperature (22°C) for 15 minutes prior to initiation of the enzymatic reaction by the addition of 20 μ L of a sonicated solution of 1

25 mM arachidonic acid (AA) and 1 mM TMPD in assay buffer (without enzyme or hematin). The enzymatic activity is measured by estimation of the initial velocity of TMPD oxidation over the first 36 sec of the reaction. A non-specific rate of oxidation is observed in the absence of enzyme (0.007 - 0.010 O.D. /min) and is subtracted before the calculation

30 of the % inhibition. IC50 values are derived from 4-parameter least squares non-linear regression analysis of the log-dose vs % inhibition plot.

HUMAN WHOLE BLOOD ASSAY

35

Rationale

Human whole blood provides a protein and cell-rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory compounds such as selective COX-2 inhibitors. Studies have shown that normal human blood does not contain the COX-2 enzyme. This is 5 consistent with the observation that COX-2 inhibitors have no effect on PGE₂ production in normal blood. These inhibitors are active only after incubation of human whole blood with LPS, which induces COX-2. This assay can be used to evaluate the inhibitory effect of selective COX-2 inhibitors on PGE₂ production. As well, platelets in whole blood contain 10 a large amount of the COX-1 enzyme. Immediately following blood clotting, platelets are activated through a thrombin-mediated mechanism. This reaction results in the production of thromboxane B₂ (TxB₂) via activation of COX-1. Thus, the effect of test compounds on TxB₂ levels following blood clotting can be examined and used as an 15 index for COX-1 activity. Therefore, the degree of selectivity by the test compound can be determined by measuring the levels of PGE₂ after LPS induction (COX-2) and TxB₂ following blood clotting (COX-1) in the same assay.

20 Method

A. COX-2 (LPS-induced PGE₂ production)

Fresh blood is collected in heparinized tubes by 25 venipuncture from both male and female volunteers. The subjects have no apparent inflammatory conditions and have not taken any NSAIDs for at least 7 days prior to blood collection. Plasma is immediately obtained from a 2mL blood aliquot to use as blank (basal levels of PGE₂). The remaining blood is incubated with LPS (100 µg/ml final concentration, Sigma Chem, #L-2630 from E. coli; diluted in 0.1% BSA (Phosphate buffered saline) for 5 minutes at room temperature. Five 30 hundred µL aliquots of blood are incubated with either 2µL of vehicle (DMSO) or 2µL of a test compound at final concentrations varying from 10nM to 30µM for 24 hours at 37°C. At the end of the incubation, the blood is centrifuged at 12,000 x g for 5 minutes to obtain plasma. A 100µL aliquot of plasma is mixed with 400µL of methanol for protein 35 precipitation. The supernatant is obtained and is assayed for PGE₂ using a radioimmunoassay kit (Amersham, RPA#530) after conversion

of PGE₂ to its methyl oximate derivative according to the manufacturer's procedure.

B. COX-1 (Clotting-induced TxB₂ production)

5 Fresh blood is collected into vacutainers containing no anticoagulants. Aliquots of 500 μ L are immediately transferred to siliconized microcentrifuge tubes preloaded with 2 μ L of either DMSO or a test compound at final concentrations varying from 10nM to 30 μ M. The tubes are vortexed and incubated at 37°C for 1 hour to allow blood to 10 clot. At the end of incubation, serum is obtained by centrifugation (12,000 x g for 5 min.). A 100 μ L aliquot of serum is mixed with 400 μ L of methanol for protein precipitation. The supernatant is obtained and is assayed for TxB₂ using a enzyme immunoassay kit (Cayman, #519031) according to the manufacturer's instruction.

15

RAT PAW EDEMA ASSAY

Protocol

Male Sprague-Dawley rats (150-200 g) are fasted overnight 20 and are given, po, either vehicle (1% methocel or 5% Tween 80) or a test compound. One hr later, a line is drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (V₀) is measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water 25 displacement. The animals are then injected subplantarly with 50 μ l of 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e. 500 μ g carrageenan per paw). Three hr later, the paw volume (V₃) is measured and the increases in paw volume (V₃ - V₀) are calculated. The animals are 30 sacrificed by CO₂ asphyxiation and the absence or presence of stomach lesions scored. Data is compared with the vehicle-control values and percent inhibition calculated. All treatment groups are coded to eliminate observer bias.

35 **NSAID-INDUCED GASTROPATHY IN RATS**

Rationale

The major side effect of conventional NSAIDs is their ability to produce gastric lesions in man. This action is believed to be caused by inhibition of Cox-1 in the gastrointestinal tract. Rats are particularly 5 sensitive to the actions of NSAIDs. In fact, rat models have been used commonly in the past to evaluate the gastrointestinal side effects of current conventional NSAIDs. In the present assay, NSAID-induced gastrointestinal damage is observed by measuring fecal ^{51}Cr excretion after systemic injection of ^{51}Cr -labeled red blood cells. Fecal ^{51}Cr 10 excretion is a well-established and sensitive technique to detect gastrointestinal integrity in animals and man.

Methods

Male Sprague Dawley rats (150 - 200 g) are administered 15 orally a test compound either once (acute dosing) or b.i.d. for 5 days (chronic dosing). Immediately after the administration of the last dose, the rats are injected via a tail vein with 0.5 mL of ^{51}Cr -labeled red blood cells from a donor rat. The animals are placed individually in metabolism cages with food and water *ad lib.* Feces are collected for a 48 20 h period and ^{51}Cr fecal excretion is calculated as a percent of total injected dose. ^{51}Cr -labeled red blood cells are prepared using the following procedures. Ten mL of blood is collected in heparinized tubes via the vena cava from a donor rat. Plasma is removed by centrifugation and replenished with equal volume of HBSS. The red blood cells are 25 incubated with 400 μCi of sodium $^{51}\text{chromate}$ for 30 min. at 37°C. At the end of the incubation, the red blood cells are washed twice with 20 mL HBSS to remove free sodium $^{51}\text{chromate}$. The red blood cells are finally reconstituted in 10 mL HBSS and 0.5 mL of the solution (about 20 μCi) is injected per rat.

30

PROTEIN-LOSING GASTROPATHY IN SQUIRREL MONKEYSRationale

Protein-losing gastropathy (manifested as appearance of 35 circulating cells and plasma proteins in the GI tract) is a significant and dose-limiting adverse response to standard non-steroidal anti-inflammatory drugs (NSAIDs). This can be quantitatively assessed by

intravenous administration of $^{51}\text{CrCl}_3$ solution. This isotopic ion can avidly bind to cell and serum globins and cell endoplasmic reticulum. Measurement of radioactivity appearing in feces collected for 24 h after administration of the isotope thus provides a sensitive and quantitative index of protein-losing gastropathy.

Methods

Groups of male squirrel monkeys (0.8 to 1.4 kg) are treated by gavage with either 1% methocell or 5% Tween 80 in H₂O vehicles, 10 (3mL/kg b.i.d.) or test compounds at doses from 1 - 100 mg/kg b.i.d. for 5 days. Intravenous ^{51}Cr (5 $\mu\text{Ci}/\text{kg}$ in 1 ml/kg phosphate buffer saline (PBS)) is administered 1 h after the last drug/vehicle dose, and feces collected for 24 h in a metabolism cage and assessed for excreted ^{51}Cr by gamma-counting. Venous blood is sampled 1 h and 8 h after the last 15 drug dose, and plasma concentrations of drug measured by RP-HPLC.

LPS-Induced Pyrexia in Conscious Rats

Male Sprague-Dawley rats (150 - 200 g) were fasted for 16 - 18 h before use. At approximately 9:30 a.m., the animals were placed 20 temporarily in plexiglass restrainers and their baseline rectal temperature was recorded using a flexible temperature probe (YSI series 400) connected to a digital thermometer (Model 08502, Cole Parmer). The same probe and thermometer were used for all animals to reduce experimental error. The animals were returned to their cages 25 after the temperature measurements. At time zero, the rats were injected intraperitoneally with either saline or LPS (2 mg/kg, Sigma Chem) and the rectal temperature was remeasured at 5, 6 and 7 h following LPS injection. After the measurement at 5 h, when the increase in temperature had reached a plateau, the LPS-injected rats 30 were given either the vehicle (1% methocel) or a test compound orally to determine whether the compound could reverse the pyrexia. Percent reversal of the pyrexia was calculated using the rectal temperature obtained at 7 h in the control (vehicle-treated) group as the reference (zero reversal) point. Complete reversal of pyrexia to the pre-LPS 35 baseline value is taken as 100%.

LPS-Induced Pyrexia in Conscious Squirrel Monkeys

Temperature probes were surgically implanted under the abdominal skin in a group of squirrel monkeys (*Saimiri sciureus*) (1.0 - 1.7 kg). This allows for the monitoring of body temperature in conscious, 5 unrestrained monkeys by a telemetric sensing system (Data Sciences International, Minnesota). The animals were fasted and were placed in individual cages for acclimatization 13 - 14 h before use. Electronic receivers were installed on the side of the cages which pick up signals from the implanted temperature probes. At approximately 9:00 a.m. on 10 the day of the experiment, the monkeys were restrained temporarily in training chairs and were given a bolus I.V. injection of LPS, (6 μ g/kg, dissolved in sterile saline). The animals were returned to their cages and body temperature was recorded continuously every 5 min. Two h after injection of LPS, when the body temperature had increased by 1.5 - 15 2°C, the monkeys were dosed orally with either vehicle (1% methocel) or a test compound (3 mg/kg). One hundred minutes later, the difference between the body temperature and the baseline value was determined. Percent inhibition was calculated taking the value in the control group as 0% inhibition.

20

Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats

Experiments were performed using male Sprague Dawley rats (90-110g). Hyperalgesia to mechanical compression of the hind paw was induced by intraplantar injection of carrageenan (4.5 mg into one hind paw) 3 h previously. Control animals received an equivalent volume of saline (0.15 ml intraplantar). A test compound (0.3-30 mg/kg, suspended in 0.5% methocel in distilled water) or vehicle (0.5% methocel) was administered orally (2ml/kg) 2 h after carrageenan. The vocalisation response to compression of the hind paw was measured 1 h later using a Ugo Basile algesiometer.

Statistical analysis for carrageenan-induced hyperalgesia was performed using one-way ANOVA (BMDP Statistical Software Inc.). Hyperalgesia was determined by subtracting the vocalisation threshold in saline injected rats from that obtained in animals injected with carrageenan. Hyperalgesia scores for drug-treated rats were expressed as a percentage of this response. ID₅₀ values (the dose producing 50% of the maximum observed response) were then calculated by nonlinear least squares regression analysis of mean data using GraFit (Erihacus Software).

20

Adjuvant-Induced Arthritis in Rats

Seventy, 6.5-7.5 week old, female Lewis rats (body weight ~146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of *Mycobacterium butyricum* in 0.1 ml of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 ml of a combination of Ketamine (87

mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were 5 evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) 10 subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, Indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% 15 methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.

Two-factor ('treatment' and 'time') analysis of variance 20 with repeated measures on 'time' were applied to the % changes for body weight and foot volumes and to the rank-transformed radiographic total scores. A *post hoc* Dunnett's test was conducted to compare the effect of treatments to vehicle. A one-way analysis of variance was applied to the thymic and spleen weights followed by the Dunnett's test to compare the 25 effect of treatments to vehicle. Dose-response curves for % inhibition in foot volumes on days 4, 14 and 21 were fitted by a 4-parameter logistic function using a nonlinear least squares' regression. ID₅₀ was defined as the dose corresponding to a 50% reduction from the vehicle and was derived by interpolation from the fitted 4-parameter equation.

PHARMACOKINETICS IN RATS

Per Os Pharmacokinetics in Rats

5 **PROCEDURE:**

The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.

10 Male Sprague Dawley rats (325-375 g) are fasted overnight prior to each PO blood level study.

The rats are placed in the restrainer one at a time and the box firmly secured. The zero blood sample is obtained by nicking a small (1 mm or less) piece off the tip of the tail. The tail is then stroked with a firm but gentle motion from the top to the bottom to milk out the blood.

15 Approximately 1 mL of blood is collected into a heparinized vacutainer tube.

Compounds are prepared as required, in a standard dosing volume of 10mL/kg, and administered orally by passing a 16 gauge, 3" gavaging needle into the stomach.

20 Subsequent bleeds are taken in the same manner as the zero bleed except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and milked/stroked as described above into the appropriately labelled tubes.

25 Immediately after sampling, blood is centrifuged, separated, put into clearly marked vials and stored in a freezer until analysed.

Typical time points for determination of rat blood levels after PO dosing are:

0, 15min, 30min, 1h, 2h, 4h, 6h

30 After the 4 hr time point bleed, food is provided to the rats *ad libitum*. Water is provided at all times during the study.

Vehicles:

The following vehicles may be used in PO rat blood level determinations:

5

PEG 200/300/400: restricted to 2 mL/kg

Methocel 0.5% - 1.0%: 10mL/kg

Tween 80: 10mL/kg

10

Compounds for PO blood levels can be in suspension form. For better dissolution, the solution can be placed in a sonicator for approximately 5 minutes.

15

For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection. Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability (F) is assessed by comparing area under the curve (AUC) i.v. versus p.o.

20

$$F = \frac{AUC_{po} \times DOSE_{iv} \times 100\%}{AUC_{iv} \quad DOSE_{po}}$$

Clearance rates are calculated from the following relation:

25

$$CL = \frac{DOSE_{iv}(\text{mg/kg})}{AUC_{iv}}$$

The units of CL are mL/h•kg (milliliters per hour

kilogram)

30

Intravenous Pharmacokinetics in Rats**PROCEDURE:**

5 The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.

Male Sprague Dawley (325-375 g) rats are placed in plastic shoe box cages with a suspended floor, cage top, water bottle and food.

10

The compound is prepared as required, in a standard dosing volume of 1 mL/kg.

Rats are bled for the zero blood sample and dosed under CO₂ sedation. The rats, one at a time, are placed in a primed CO₂ chamber 15 and taken out as soon as they have lost their righting reflex. The rat is then placed on a restraining board, a nose cone with CO₂ delivery is placed over the muzzle and the rat restrained to the board with elastics. With the use of forceps and scissors, the jugular vein is exposed and the zero sample taken, followed by a measured dose of compound which is 20 injected into the jugular vein. Light digital pressure is applied to the injection site, and the nose cone is removed. The time is noted. This constitutes the zero time point.

The 5 min bleed is taken by nicking a piece (1-2 mm) off the tip of the tail. The tail is then stroked with a firm but gentle motion from 25 the top of the tail to the bottom to milk the blood out of the tail.

Approximately 1 mL of blood is collected into a heparinized collection vial. Subsequent bleeds are taken in the same fashion, except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and bled, as described above, into the appropriate labelled tubes.

30

Typical time points for determination of rat blood levels after I.V. dosing are either:

0, 5 min, 15min, 30min, 1h, 2h, 6h

or

0, 5 min, 30min, 1h, 2h, 4h, 6h.

35

Vehicles:

The following vehicles may be used in IV rat blood level determinations:

Dextrose: 1mL/kg

5 2-Hydroxypropyl- β -cyclodextrin 1mL/kg

DMSO (dimethylsulfoxide): Restricted to a dose volume of 0.1 mL per animal

PEG 200: Not more than 60% mixed with 40% sterile water - 1mL/kg

10

With Dextrose, either sodium bicarbonate or sodium carbonate can be added if the solution is cloudy.

For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection. Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability (F) is assessed by comparing area under the curve (AUC) i.v. versus p.o.

20

$$F = \frac{AUC_{po}}{AUC_{iv}} \times \frac{DOSE_{iv}}{DOSE_{po}} \times 100\%$$

Clearance rates are calculated from the following relation:

25

$$CL = \frac{DOSEiv(\text{mg/kg})}{AUCiv}$$

The units of CL are mL/h•kg (milliliters per hour kilogram)

30

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

(i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C,

(ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60°C..

(iii) the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only:

(iv) melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations;

5 (v) the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data;

10 (vi) yields are given for illustration only;

(vii) when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; 15 m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal;

20 (viii) chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (litre(s)), mL (millilitres), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

EXAMPLES

25 Examples 1, 5, 7, 9, 11, 13 and 17 were prepared according to the sequence of reactions described for Example 3 by replacing benzoyl chloride in Step 1 with the appropriate aroyl chloride and/or 4-methyl-4-hydroxyvaleric acid γ -lactone in Step 2 with the appropriate γ -butyrolactone.

30 Examples 2, 6, 8, 10, 12 and 14 were obtained by chromatographic separation at the Step 4 in the preparation of Examples 1, 5, 7, 9, 11 and 13 respectively.

4-methyl-4-hydroxyvaleric acid γ -lactone, , Tscheschlok, K., Bäuml, K., Pock, R., Mayr, H. *Tet. Lett.*, 29, 6925, 1988.

35 3,3-Dimethyl- γ -butyrolactone, Bailey, D.M., Johnson, R.E., *J. Org. Chem.*, 35, 3574, 1970.

EXAMPLE 1

5 3-[(E)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethylidenetetrahydro-2-furanone

m.p. 146-147°C, Analysis calculated for C₁₈H₁₆O₄S
C, 65.84; H, 4.91, S, 9.76 Found: C, 65.73; H, 5.00; S, 10.00

10

EXAMPLE 2

3-[(Z)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethylidenetetrahydro-2-furanone

15 m.p. 211-212°C, Analysis calculated for C₁₈H₁₆O₄S.
C, 65.84; H, 4.91; S, 9.76 Found: C, 65.75; H, 5.01; S, 9.97

EXAMPLE 3

20 5,5-Dimethyl-3-[(E)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidenetetrahydro-2-furanone

Step 1: (4-(Methylthio)phenyl) phenyl ketone

25 A 3 L RBF equipped with a mechanical stirrer was charged with AlCl₃ (152 g) and CHCl₃ (1.4 L) and cooled in an ice bath. Then benzoyl chloride (139 mL) was added over 0.5 h to the ice-cold suspension. Keeping the internal temp. <10°C, thioanisole was added dropwise over 1 hr. After completion of addition, the resulting mixture was stirred at r.t. for 2 h. The resulting dark red-orange suspension 30 was poured onto an ice-water mixture and stirred until decoloration. The organic layer was separated, washed with water, saturated NaHCO₃, brine, dried over Na₂SO₄ and concentrated to dryness. The resulting white solid was swished in hexane (500 mL) collected by filtration to give the title compound as a white solid.

35 ¹H NMR (CD₃COCD₃): δ 2.59 (3H, s), 7.41 (2H, d), 7.55 (2H, t), 7.64 (1H, m), 7.75 (4H, m).

Step 2: 3-[Hydroxy(4-(methylthio)phenyl)phenylmethyl]-5,5-dimethyltetrahydro-2-furanone, mixture of erythro and threo isomers

5 To a solution of 1.0 M LDA (3.9 mL) cooled to -78°C, was added dropwise a solution of 4-methyl-4-hydroxyvaleric acid γ -lactone (440 mg) in THF (4 mL) over 5 min. and the reaction was allowed to proceed at this temp. for 0.5 h. Then a solution of (4-(methylthio)phenyl) phenyl ketone (905 mg) from Step 1, in THF (4 mL) was added dropwise 10 and the resulting mixture was stirred at -78°C for 2 h. The reaction was treated with a 25% aqueous solution of NH₄OAc (50 mL) and extracted with EtOAc (2x50 mL). The organic layer was dried over MgSO₄ and concentrated. The crude product was partly purified by filtration on a 15 plug of silica gel eluted with 20% EtOAc in hexane to give the title compound as a light yellow solid mixture of diastereomers.

¹H NMR (CD₃COCD₃): δ 1.34 and 1.42 (6H, 2s), 1.95 (1H, m), 2.11 (1H, m), 2.45 (3H, s), 4.45 (1H, dd), 4.67 (1H, s), 7.18 (3H, m), 7.27 (2H, q), 7.44 (1H, d), 7.51 (1H, d), 7.56 (1H, d), 7.61 (1H, d).

20 **Step 3: 5,5-Dimethyl-[3{1-(4-(methylthio)phenyl)-1-phenylmethylidene]tetrahydro-2-furanone, mixture of E and Z isomers.**

To a solution of the tertiary alcohol obtained from Step 2 (929 mg) in dichloroethane (25 mL), was added Et₃N (1.7 mL) followed by 25 methanesulfonyl chloride (0.8 mL). The resulting mixture was stirred at 70°C for 20 h, allowed to cool to r.t., diluted with water (100 mL) and extracted with EtOAc (2x 75 mL). The organic layer was dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography (10% EtOAc in toluene) to give the title compound. 30 ¹H NMR (CD₃COCD₃): δ 1.42 (6H, 2s), 2.52 (3H, 2s), 2.93 and 2.99 (2H, 2s), 7.08 - 7.41 (9H, m).

Step 4: 5,5-Dimethyl-3-[{(E)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidene]tetrahydro-2-furanone

35 To an ice-cold solution of the methylthio compound obtained from Step 3 (660 mg) in CH₂Cl₂ (18 mL) and MeOH (2 mL) was added

MMPP (1165 mg of 80% pure). The resulting mixture was stirred at r.t. for 20 h. The reaction was diluted with EtOAc (150 mL) and half saturated NaHCO₃ (100 mL). The mixture was shaken vigorously, layers separated, the organic layer was dried over MgSO₄ and 5 concentrated. The crude product was swished in EtOAc (30 mL) to give the fast eluting Z isomer pure, as a white solid. The mother liquors were concentrated and purified by flash chromatography (slow eluting product in 80% - 90% - 100% Et₂O in hexane) and then swished in a 1:1 mixture of EtOAc/hexane (10 mL) to afford the title compound as a white 10 solid.

¹H NMR (CD₃COCD₃): δ 1.44 (6H, s), 3.00 (2H, s), 3.16 (3H, s), 7.21 (2H, m), 7.33 (3H, m), 7.53 (2H, dd), 7.98 (2H, dd).

Geometry of the olefin was assigned by a nOe experiments.

15 EXAMPLE 4

5,5-Dimethyl-3-[*(Z*)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethyl-ideneltetrahydro-2-furanone

The title compound was obtained as a white solid from the 20 first swish (30 mL of EtOAc) in Step 4 of Example 3.

¹H NMR (CD₃COCD₃): δ 1.45 (6H, s), 3.03 (2H, s), 3.13 (3H, s), 7.28 (2H, dd), 7.42 (5H, m), 7.90 (2H, d).

Geometry of the olefin was assigned by nOe experiments.

25 EXAMPLE 5

3-[*(E*)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)methyl-ideneltetrahydro-2-furanone

30 m.p. 186-187°C, Analysis calculated for C₁₈H₁₅FO₄S
C 62.42; H, 4.37; S, 9.26 Found: C, 62.72; H, 4.38; S, 9.56

EXAMPLE 6

35 3-[*(Z*)-1-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]methyl-ideneltetrahydro-2-furanone.

m.p. 150°C, Analysis calculated for C₁₈H₁₅FO₄S
C, 62.42; H, 4.37; S, 9.26 Found: C, 62.83, H, 4.40; S, 9.57.

5

EXAMPLE 7

3-[(Z)-1-(3-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]methylidenetetrahydro-2-furanone

10 m.p. 150-151°C, Analysis calculated for C₁₈H₁₅FO₄S
C, 62.42; H, 4.37; S, 9.26 Found: C, 62.60; H, 4.50; S, 9.69

EXAMPLE 8

15 3-[(E)-1-(4-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]methylidene]tetrahydro-2-furanone

m.p. 197°C, Analysis calculated for C₁₈H₁₅FO₄S
C, 62.42; H, 4.37; S, 9.26 Found: C, 62.57; H, 4.59; S, 9.81

20

EXAMPLE 9

5-Methyl-3-[(E)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidene]tetrahydro-2-furanone, Racemic at C-5.

5

m.p. 132-133°C, Analysis for C₁₉H₁₈O₄S
C, 66.65; H, 5.30; S, 9.36 Found C, 66.68; H, 5.35; S, 9.54.

EXAMPLE 10

10

5-Methyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidene]tetrahydro-2-furanone, racemic at C-5.

15

m.p. 219°C, Analysis calculated for C₁₉H₁₈O₄S
C, 66.65; H, 5.30; S, 9.36 Found C, 66.53; H, 5.12; S, 9.19

EXAMPLE 11

20

3-[(E)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)methylidene]-5,5-dimethyltetrahydro-2-furanone

m.p. 173°C, Analysis calculated for C₂₀H₁₉FO₄S
C, 64.16; H, 5.11; S, 8.56 Found: C, 64.00; H, 5.17; S, 8.56

25

EXAMPLE 12

3-[(Z)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)methylidene]-5,5-dimethyltetrahydro-2-furanone

30

m.p. 244°C, Analysis calculated for C₂₀H₁₉FO₄S
C, 64.16; H, 5.11; S, 8.56 Found: C, 64.00; H, 5.14; S, 8.71

EXAMPLE 133-[(Z)-1-(3-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)methylidene]-5,5-dimethyltetrahydro-2-furanone

5

m.p. 168°C, Analysis calculated for C₂₀H₁₉FO₄S
C, 64.16; H, 5.11; S, 8.56 Found: C, 64.04; H, 5.25; S, 8.61.

EXAMPLE 14

10

3-[(E)-1-(3-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)methylidene]-5,5-dimethyltetrahydro-2-furanone

15

m.p. 230-231°C, Analysis calculated for C₂₀H₁₉FO₄S
C, 64.16; H, 5.11; S, 8.56 Found: C, 63.90; H, 5.14; S, 8.55

EXAMPLE 15

20

5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(2-pyridyl)-methylidene] tetrahydro-2-furanoneStep 1: [4-(Methylthio)phenyl](2-pyridyl)methanol

A solution of 4-bromothioanisole (4.8 g) in THF (140 mL) was cooled to -78°C followed by a slow addition, over 5 min. of 2.5 M n-butyl lithium in hexane (10.2 mL). The resulting suspension was stirred at this temp. for 0.5 h. Then a solution of 2-pyridinecarboxaldehyde (2.32 g) in THF (20 mL) was added over 5 min. the resulting mixture was stirred at -78°C for 0.25 h and at r.t. for 1 h. The reaction mixture was extracted with EtOAc and 25% aqueous solution of NH₄OAc. The organic layer was dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography (50% - 60% - 70% EtOAc in hexane) to give the title compound.

¹H NMR (CD₃COCD₃): δ 2.44 (3H, s), 5.26 (1H, d), 5.78 (1H, d), 7.22 (3H, m), 7.38 (2H, d), 7.48 (1H, d), 7.73 (1H, t), 8.51 (1H, d)

35

Step 2: [4-(Methylthio)phenyl] (2-pyridyl) ketone

To a solution of the compound obtained from Step 1 (3.34 g) in EtOAc (100 mL) was added manganese (IV) oxide in 2 portions (2.50 + 2.72 g) every 24 hours. The resulting suspension was stirred at r.t. for a total of 2 days. The reaction was filtered through a pad of celite, washed 5 with EtOAc and concentrated. The crude product was purified by crystallization from 5% EtOAc in hexane (100 mL) to give the title compound.

¹H NMR (CD₃COCD₃): δ 2.58 (3H, s), 7.38 (2H, d), 7.62 (1H, dd), 7.98 - 8.05 (2H, m), 8.08 (2H, d), 8.72 (1H, d).

10

Step 3: 3-[Hydroxy(4-(methylthio)phenyl)-2-pyridylmethyl]-5,5-dimethyltetrahydro-2-furanone

Using the procedure described for Example 3, Step 2, and substituting [4-(methylthio)phenyl] (2-pyridyl) ketone obtained from Step 15 2, for [4-(methylthio)phenyl] (phenyl) ketone, the title compound was obtained as a mixture of erythro and threo isomers after flash chromatography (35% - 50% - 60% EtOAc in hexane).

Fast eluting diastereoisomer ¹H NMR (CD₃COCD₃): δ 1.38 (3H, s), 1.44 (20 3H, s), 1.82 (1H, dd)m, 2.20 (1H, td), 4.09 (1H, m), 5.82 (1H, 6s), 7.18 (2H, d), 7.28 (1H, dd), 7.50 (2H, d), 7.56 (1H, d), 7.79 (1H, td), 8.50 (1H, d).

Slow eluting diastereoisomer ¹H NMR (CD₃COCD₃): δ 1.40 (6H, s), 2.10 (2H, m), 2.44 (3H, s), 4.60 (1H, t), 6.75 (1H, bs), 7.20 (2H, d), 7.22 (1H, m), 25 7.63 (2H, d), 7.77 (2H, m), 8.46 (1H, d).

Step 4: 5,5-Dimethyl-3-[*(Z*)-1-[4-(methylthio)phenyl]-1-(2-pyridyl)methylidene]tetrahydro-2-furanone

To a solution of the tertiary alcohols obtained from Step 30 3 (351 mg) in CH₂Cl₂ (10 mL) was added dropwise trifluoromethane sulfonic acid (0.6 mL). The reaction was allowed to proceed at r.t. for 0.5 h. The reaction mixture was diluted with Et₃N (2 mL) and the mixture was concentrated in vacuo. The crude product was purified by flash chromatography (50% - 70% EtOAc in hexane) to give the title compound 35 as a gum that solidified upon standing at r.t.

¹H NMR (CD₃COCD₃): δ 1.42 (6H, s), 2.50 (3H, s), 3.07 (2H, s), 7.19 (2H, d), 7.23-7.32 (4H, m), 7.71 (1H, t), 8.53 (1H, d).

5 Step 5: 5,5-Dimethyl-3-[*Z*]-1-(4-(methylsulfonyl)phenyl)-1-(2-pyridyl)methylidenetetrahydro-2-furanone

To a solution of the furanone obtained from Step 4 (436 mg) in MeOH (30 mL) was added a solution of OXONE™ (1.18 g) in water (15 mL). The resulting suspension was stirred at r.t. for 1 h. The reaction was diluted with water and extracted with EtOAc. The organic layer was dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography (90% - 100% EtOAc in hexane) to give the title compound as a colorless gum. It was further purified by crystallization from a 1:1 mixture of EtOAc and hexane (14 mL) to give a white solid.

15 m.p. 177°C, Analysis calculated for C₁₉H₁₉NO₄S
C, 63.85; H, 5.36; N, 3.92; S, 8.97 Found: C, 63.55; H, 5.33; N, 3.87; S, 9.36

EXAMPLE 16

20 3-[*Z*]-1-(4-Chlorophenyl)-1-[4-(methylsulfonyl)phenyl]methylidene]-5,5-dimethyltetrahydro-2-furanone

m.p. 126-127°C, MS (APCI, 3:1 MeOH/aqueous NH₄OAc) m/z calculated for M⁺, 390 Found for M⁺ +1, 391.

25

EXAMPLE 17

30 4,4-Dimethyl-3-[1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidenetetrahydro-2-furanone, 1:1 mixture of E and Z isomers.

35 MS (APCI, 3:1 MeOH/Aqueous NH₄OAc) m/z calculated for M⁺, 356 found for M⁺ +1, 357.

EXAMPLE 18

35

4-[Cyclopentylidene]phenylmethylsulfone

Step 1: Cyclopentyl [4-(methylsulfonyl)phenyl] ketone

Using the procedure described for Example 3, Step 1, and substituting cyclopentanecarbonyl chloride for benzoyl chloride, the title compound was obtained as a beige solid.

5 ^1H NMR (CD₃COCD₃): δ 1.65 (4H, m), 1.75 - 1.95 (4H, m), 2.53 (3H, s), 3.88 (1H, m), 7.34 (2H, d), 7.92 (2H, d).

Step 2: Cyclopentyl[4-(methylsulfonyl)phenylphenylmethanol

10 A solution of the ketone obtained from Step 1 (3.52 g) in Et₂O (50 mL) was cooled to -78°C and was slowly added a 1.8 M solution of phenyl lithium in cyclohexane Et₂O (7:3) (10.0 mL). The reaction was allowed to proceed for 0.25 h. The reaction was diluted with 25% aqueous solution of NH₄OAc and extracted with EtOAc. The organic layer was 15 washed once with water, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography (7% EtOAc in hexane) to give the title compound as a yellow oil.

1 ^1H NMR (CD₃COCD₃): δ 1.47 - 1.62 (8H, bm), 2.42 (3H, s), 3.25 (1H, bm), 4.21 (1H, s), 7.08 - 7.16 (3H, m), 7.26 (2H, dd), 7.50 (2H, d), 7.56 (2H, d).

20 Step 3: 4-[Cyclopentyliden(phenyl)methyl]phenyl methyl sulfide
To a solution of the tertiary alcohol obtained from Step 2 (4.52 g) in CH₂Cl₂ (50 mL) was added dropwise trifluoromethane sulfonic acid (0.1 mL) and the reaction was allowed to proceed for 0.5 h. 25 Et₃N (0.5 mL) was added and the solvents were removed in vacuo. The resulting crude product was purified by flash chromatography (5% EtOAc in hexane) to give the title compound as a colorless gum.
 ^1H NMR (CD₃COCD₃): δ 1.17 (4H, m), 2.38 (4H, m), 2.49 (3H, s), 7.12 (2H, d), 7.19 (5H, q), 7.32 (2H, t).

30 Step 4: 4-[Cyclopentyliden(phenyl)methyl]phenyl methyl sulfone
Using the procedure described for Example 3, Step 4, and substituting 4-[cyclopentyliden(phenyl)methyl]phenyl methyl sulfide obtained from Step 3, for 5,5-dimethyl-3[1-(4-(methylthio)phenyl)-1-35 phenylmethylidene]tetrahydro-2-furanone, the title compound was obtained as a colorless gum.

¹H NMR (CD₃COCD₃): δ 1.66 - 1.73 (4H, m), 2.37 - 2.45 (4H, m), 3.10 (3H, s), 7.20 (2H, d), 7.25 (1H, d), 7.34 (2H, t), 7.46 (2H, d), 7.88 (2H, d).

EXAMPLE 19

5

2[(E)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethylidenel-1-cyclopentanone

Chromium trioxide (4.04 g) was suspended in CH₂Cl₂ (35 mL) at -20°C and 3,5-dimethylpyrazole was added in one portion. After 10 stirring for 0.25 h at -20°C, a solution of the compound described in Example 18 (615 mg) in CH₂Cl₂ (4 mL) was added and the reaction mixture was stirred for 1 h while maintaining the temperature at -20°C. Sodium hydroxide (15 mL, 5N) was added and the mixture was stirred for 1 h at 0°C. The reaction was diluted with water and extracted with 15 CH₂Cl₂. The organic layer was washed once with 1N HCl, once with water, once with brine, dried over MgSO₄ and concentrated. The crude product was purified by flash chromatography (30% - 40% - 50% - 60% EtOAc in hexane) to give 5 compounds one of which was a mixture of the title compound and the compound described in Example 20, R_f 0.10 - 20 0.08 (30% EtOAc in hexane). These two compounds were separated by preparative HPLC using a Waters μ-porasil column and 40% EtOAc in hexane as eluant. The fast eluting isomer was the title compound. The double bond geometry was assigned by nOe experiments.
High: Res MS, m/z calculated for C₁₉H₁₈O₃S+H⁺ 327.10549 Found 25 327.10558

EXAMPLE 20

30

2-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidenel-1-cyclopentanone

35

The title compound was obtained as the slow eluting isomer during the preparative HPLC separation of Example 19. The double bond geometry was assigned by nOe experiments High, Res. MS, m/z calculated for C₁₉H₁₈O₃S+H⁺ 327.10549 Found 327.10558

EXAMPLE 21

5.5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(3-pyridyl)methyl-
5 idenyl tetrahydro-2-furanone

Using the procedures described for the preparation of Example 15 and substituting 3-pyridinecarboxaldehyde for 2-pyridinecarboxaldehyde in Step 1, the title compound was obtained as a white solid.

10 m.p. 163 - 164°C, Analysis calculated for C₁₉H₁₉NO₄S
C, 68.85; H, 5.36; N, 3.92 Found: C, 63.71; H, 5.24; N, 3.87.

EXAMPLE 22

15 5.5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(4-pyridylmethyl-
idenyl tetrahydro-2-furanone

Using the procedure described for the preparation of Example 15 and substituting 4-pyridinecarboxaldehyde for 2-pyridinecarboxaldehyde in Step 1, the title compound was obtained as a white solid.
20 m.p. 151°C


EXAMPLE 23

25 4-[Cyclobutyliden(phenyl)methyl]phenyl methyl sulfone

Using the procedure described for the preparation of Example 18 and substituting cyclobutanecarbonyl chloride for cyclopentanecarbonyl chloride in Step 1, the title compound was obtained
30 as a white solid.
m.p. 121°C

WHAT IS CLAIMED IS:

1. A compound of Formula I



5

or a pharmaceutically acceptable salt thereof wherein
X is selected from the group consisting of

- (a) O,
- (b) CH₂,
- 10 (c) CH(C₁₋₃alkyl),
- (d) C(C₁₋₃alkyl)₂, and
- (e) a bond;

Y is selected from the group consisting of

- (a) O,
- 15 (b) H,
- (c) OH, H;

Ar is selected from the group consisting of

- (a) phenyl, and
- (b) pyridyl;

20 each of R¹, R², R³, or R⁴ is independently selected from

- (a) hydrogen or,
- (b) C₁₋₆alkyl;

each of R⁵ or R⁶ is independently selected from

- (a) hydrogen,
- 25 (b) halo,
- (c) C₁₋₄alkyl,
- (d) C₁₋₄alkoxy, and
- (e) C₁₋₄alkylthio;

R⁷ is

30 (a) NH₂ or

(b) CH₃.

2. A compound according to Claim 1 wherein X is O.
- 5 3. A compound according to Claim 1 wherein Y is O.
4. A compound according to Claim 1 wherein X and Y are both O.
- 10 5. A compound according to Claim 1 wherein R¹ and R² are both CH₃.
6. A compound according to Claim 1 wherein R⁵ is hydrogen or F.
- 15 7. A compound according to Claim 1 wherein R⁷ is CH₃.
8. A compound according to Claim 1 selected from the 20 group consisting of
3-[(E)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethylidene]-tetrahydro-2-furanone,
5,5-Dimethyl-3-[(E)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidene]tetrahydro-2-furanone,
25 3-[(E)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-methylidene]tetrahydro-2-furanone,
3-[(Z)-1-(3-Fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-methylidene]tetrahydro-2-furanone,
30 5-Methyl-3-[(E)-1-(4-(methylsulfonyl)phenyl)-1-phenylmethylidene]tetrahydro-2-furanone,
3-[(E)-1-(4-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-methylidene]-5,5-dimethyltetrahydro-2-furanone,
35 3-[(Z)-1-(3-Fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-methylidene]-5,5-dimethyltetrahydro-2-furanone,
5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(2-pyridyl)methylidene] tetrahydro-2-furanone,

3-[(Z)-1-(4-Chlorophenyl)-1-[4-(methylsulfonyl)phenyl]-methylidene]-5,5-dimethyltetrahydro-2-furanone,
4,4-Dimethyl-3-[1-(4-(methylsulfonyl)phenyl)-1-phenyl-methylidene]tetrahydro-2-furanone,
5 4-[Cyclopentyliden(phenyl)methyl]phenyl methyl sulfone,
2[(E)-1-(4-(Methylsulfonyl)phenyl)-1-phenylmethylidene]-1-cyclopentanone,
5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(3-pyridyl)methylidene] tetrahydro-2-furanone,
10 5,5-Dimethyl-3-[(Z)-1-(4-(methylsulfonyl)phenyl)-1-(4-pyridylmethylidene) tetrahydro-2-furanone, and
4-[Cyclobutyliden(phenyl)methyl]phenyl methyl sulfone.

9. A pharmaceutical composition for treating an
15 inflammatory disease susceptible to treatment with an non-steroidal
anti-inflammatory agent comprising:
a non-toxic therapeutically effective amount of a compound according to
any one of Claims 1 to 8 and a pharmaceutically acceptable carrier.

20 10. A pharmaceutical composition for treating
cyclooxygenase mediated diseases advantageously treated by an active
agent that selectively inhibits COX-2 in preference to COX-1 comprising:
a non-toxic therapeutically effective amount of a compound according to
any one of Claims 1 to 8 and a pharmaceutically acceptable carrier.

25 11. A method of treating an inflammatory disease
susceptible to treatment with an non-steroidal anti-inflammatory agent
comprising:
administration to a patient in need of such treatment of a non-toxic
30 therapeutically effective amount of a compound according to Claim 1
and a pharmaceutically acceptable carrier.

35 12. A method of treating cyclooxygenase mediated
diseases advantageously treated by an active agent that selectively
inhibits COX-2 in preference to COX-1 comprising:
administration to a patient in need of such treatment of a non-toxic
therapeutically effective amount of a compound according to Claim 1.

13. A non-steroidal anti-inflammatory pharmaceutical composition comprising an acceptable anti-inflammatory amount of a compound of formula (I), as defined in Claim 1, 2, 3, 4, 5, 6, 7 or 8, or a pharmaceutically acceptable salt thereof, in association with a 5 pharmaceutically acceptable carrier.

14. A selective COX-2 inhibitor pharmaceutical composition comprising an acceptable, selective COX-2 inhibiting amount of a compound of formula (I), as defined in Claim 1, 2, 3, 4, 5, 6, 7 or 8, or a pharmaceutically acceptable salt thereof, in association with a 10 pharmaceutically acceptable carrier.

15. Use of a compound of formula (I), as defined in Claim 1, 2, 3, 4, 5, 6, 7 or 8, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.

16. Use of a compound of formula (I), as defined in Claim 1, 2, 3, 4, 5, 6, 7 or 8, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cyclooxygenase mediated diseases advantageously treated by an agent that selectively inhibits COX-2 in preference to COX-1. 15

20 17. Use of a compound of formula (I), as defined in Claim 1, 2, 3, 4, 5, 6, 7 or 8, or a pharmaceutically acceptable salt thereof, as a non-steroidal anti-inflammatory agent.

25 18. Use of a compound of formula (I), as defined in Claim 1, 2, 3, 4, 5, 6, 7 or 8, or a pharmaceutically acceptable salt thereof, as a selective COX-2 inhibitor.

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/CA 98/00302

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D307/58 A61K31/34 C07D405/06 C07C317/24 C07C317/14

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>GILBERT ET AL.: "Inhibition of Prostaglandin Synthetase by Di- and Triphenylethylene Derivatives: A Structure-Activity Study" J.MED.CHEM., vol. 26, no. 5, 1983, pages 693-699, XP002069801 see page 695; table IV</p> <p>---</p> <p>FRIESEN R W ET AL: "NOVEL 1,2-DIARYLCYCLOBUTENES: SELECTIVE AND ORALLY ACTIVE COX-2 INHIBITORS" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 22, 19 November 1996, pages 2677-2682, XP000197596 see the whole document</p> <p>---</p> <p style="text-align: center;">-/-</p>	1-21
Y		1-21

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"E" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 June 1998

Date of mailing of the international search report

12/08/1998

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 98/00302

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 98 05643 A (TEULON JEAN MARIE ;LAUNAY MICHELE (FR); NICOLAI ERIC (FR); POTIN D) 12 February 1998 see the whole document ----	1,5-21
P,X	WO 97 37984 A (TEULON JEAN MARIE ;NICOLAI ERIC (FR); UNION PHARMA SCIENT APPL (FR) 16 October 1997 see the whole document -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00302

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9805643	A 12-02-1998	FR	2751964 A	06-02-1998
		AU	3944397 A	25-02-1998
		US	5686460 A	11-11-1997
WO 9737984	A 16-10-1997	FR	2747123 A	10-10-1997
		FR	2747124 A	10-10-1997
		AU	2393397 A	29-10-1997